ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C
Pink SheetThe US FDA’s user fee calendar for 2024 already features almost 60 new molecular entities and novel biologics, echoing the agency’s review workload at the beginning of 2023 – a position that contains
Generics BulletinZydus Lifesciences expects $100m in sales from specialty products like drugs for rare/orphan diseases over three to five years and will continue to pursue organic opportunities as well as acquisition
ScripZydus Lifesciences Limited expects $100m in sales from specialty products like drugs for rare/orphan diseases over three to five years and will continue to pursue organic opportunities as well as acq